The chi-squared test will be applied to evaluate the heterogeneity. If I2>50%, trials would be considered with significant heterogeneity, and subgroup analysis will be necessarily performed to assess the potential heterogeneity sources, these sources possibly include the onset time, duration, type of HF, etc.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。